If you're looking to put your money to work in June, a few ASX 200 heavyweights stand out as potential high-conviction buys.
These are companies with global reach, strong competitive advantages, and the potential to compound wealth for years to come.
Here are three ASX 200 shares analysts think investors should be buying this month.
CSL Ltd (ASX: CSL)
CSL is one of the true giants of the Australian share market. As a global leader in biotechnology, it has built a reputation for delivering life-saving therapies and innovative medical solutions across the world.
The company's flagship plasma therapies business is complemented by a growing portfolio of vaccines, innovative therapies, and leading research programs. The latter includes over US$1 billion a year spent on R&D activities to ensure it has a pipeline filled with potentially lucrative therapies.
Goldman Sachs is a fan of the company and is forecasting double-digit earnings growth in the coming years. As a result, it has put a buy rating and $304.60 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 share that could be a high-conviction buy is ResMed. It is a global leader in respiratory health. Its products improve the lives of millions of people living with sleep apnoea and chronic respiratory conditions.
The company has established a sticky, recurring revenue model through its devices and software platforms, creating a powerful ecosystem that supports patient care, improves outcomes, and keeps customers coming back. And with over a billion people believed to suffer from sleep apnoea globally, it has a significant growth runway over the next decade.
It is partly for this reason that Goldman Sachs has a conviction buy rating and $49.30 price target on its shares.
WiseTech Global Ltd (ASX: WTC)
Finally, WiseTech is a third ASX 200 share for investors to look at this month. Its flagship software platform, CargoWise, is used by the world's largest freight forwarders and logistics providers to manage complex, cross-border supply chains.
WiseTech's deep expertise in logistics software, its global customer base, and strong network effect give it a significant competitive advantage. The company also has a proven strategy of growing both organically and through targeted acquisitions, steadily expanding its global footprint and capabilities.
The team at Morgans is bullish on the company's outlook. So much so, its analysts recently put an add rating and $132.40 price target on its shares.
